-
XPENG Launches Two New Models in UK; Pony.ai Robotaxi Enters Pilot
-
Broad Clinical Labs Drives Strong Digital Engagement by Connecting Customers with Published Research Through Bioz
-
How to Turn Your Garage into Usable Living Space
-
Pilot-Founded Solara Global Jet Offers Charter, Leases and Air Cargo Nationwide and Overseas
-
Driving Global Innovation - GTDC Summit APJ Underscores Distribution's Transformative Power
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 17
-
PRAAMS AI Co-Investor Now Covers 400,000+ Global Instruments, With Responses From 3 Seconds, Cost From US$0.01, and Scalability to Millions of Users
-
Three Inaugural CombatX Champions Crowned at BRAVE CF Road to BRAVE Event in Hungary
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
-
Asian Markets Slide as AI Concerns Hit Chip Stocks
-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Godzilla Minus Zero Review: Takashi Yamazaki’s Anti-Nuclear Allegory
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
DA Demands No-Work-No-Pay for Striking Municipal Workers in Coalition Talks
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
Malta Emerges as Premier Low-Season Destination for UK Travelers
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
Ovation Science Expands with Planet 13 into Florida
Expanded License Agreement Brings Ovation's Science-Based Topicals to Largest Medical Cannabis Market in the USA
VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / July 29, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC:OVATF) ("Ovation" or the "Company"), today announced an expanded license agreement with Planet 13 Holdings, Inc. (CSE:PLTH)(OTCQX:PLNH) ("Planet 13") to bring its patented Invisicare® topical and transdermal cannabis products to the Florida market. The agreement will make Ovation's science-backed topical products available across Planet 13's extensive network of 33 Florida dispensary locations, building on the companies' on-going successful collaboration with Planet 13 in Nevada where Ovation's topicals have achieved top sales rankings statewide.
Florida, a medical cannabis market with almost one million registered patients, is projected to exceed $2.5 billion in cannabis sales in 2025. According to Headset.io, Florida is the largest medical cannabis market in the US and has the highest sales of topicals in the country. Florida's unique regulations require dispensaries to exclusively sell their own manufactured products, eliminating traditional wholesale distribution channels. This makes Planet 13's significant and expanding retail footprint of 33 dispensaries particularly valuable for market entry. The broad appeal of Ovation's topical products satisfies the widespread consumer demand for solutions to assist with everything from everyday aches, stress relief, evening relaxation and bedtime wind-down routines to workout recovery.
"Planet 13's comprehensive Florida presence creates an ideal platform for our topical products," said Terry Howlett, Ovation's President. "Their success with our products in Nevada demonstrates the market demand for effective, science-based solutions. Our products will be sold exclusively under Planet 13's brand across all Florida locations, providing immediate market access for Ovation's proprietary formulations. We know customers in Florida will be excited to see proven, effective, science-based topicals that work for multiple conditions." He added, "Ovation will earn royalty income from Planet 13's sales now in both Nevada and Florida under this expanded license agreement, positively impacting our financial results and creating value for our shareholders."
"Our experience with Ovation's topicals in Nevada has been excellent and we are excited to expand into Florida with these products. We will be launching our branded topical line shortly, expanding our brand presence and satisfying an unmet need for exceptional topicals in Florida," said Lee Fraser, Chief Administrative Officer of Planet 13. "This partnership with Ovation marks an important revenue generating opportunity, optimizes our Florida production facility, and enhances our gross margins."
Proven Technology Platform
Ovation's competitive advantage centers on its patented Invisicare® skin delivery system, developed through over two decades of pharmaceutical research. Laboratory testing demonstrated dramatically superior bioavailability compared to leading competitors - with Ovation's formulations achieving 82% cannabinoid penetration versus less than 2% for competing transdermal products tested. This proves substantially more CBD, THC and other cannabinoids are effectively delivered to and through the skin using Ovation's Invisicare technology, ensuring consumers receive maximum therapeutic benefit.
Growth Trajectory
The Florida launch with Planet 13 represents Ovation's third active market, joining existing states: Nevada (Planet 13) and Pennsylvania (PA Options for Wellness). Additional 2025 expansions are planned with licensees in Missouri and Canada, and other potential states, positioning the Company for accelerated revenue growth across multiple regulated jurisdictions. Ovation continues to seek growth opportunities in other legal markets both in the USA and internationally.
Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
About Planet 13
Planet 13 is a vertically integrated cannabis company, with award-winning cultivation, production and dispensary operations across its locations in California, Nevada, Illinois, and Florida. Home to the nation's largest dispensary, located just off The Strip in Las Vegas, Planet 13 continues to expand its footprint with the recent debut of its first consumption lounge in Las Vegas, DAZED!, the opening of its first Illinois dispensary in Waukegan, bringing cannabis experiences to the Chicago metro area. Planet 13 operates dispensaries across Florida, a key market in its expansive footprint. Planet 13's mission is to build a recognizable global brand known for world-class dispensary operations and innovative cannabis products. Licensed cannabis activity is legal in the states Planet 13 operates in but remains illegal under U.S. federal law. Planet 13's shares trade on the Canadian Securities Exchange (CSE) under the symbol PLTH and are quoted on the OTCQX under the symbol PLNH. To learn more, visit Planet13.com.
About Ovation Science Inc.
Ovation Science Inc. and its wholly-owned subsidiary; Ovation Science USA Inc., is a research and development company that develops topical and transdermal CBD/THC and other cannabinoid products which are out-licensed and also distributed under Ovation's own brands; ARLO CBD Beauty and InVibe® MD ("wellness" line); all powered by its patented Invisicare® skin delivery technology. Invisicare enhances the delivery of ingredients to and through the skin and is protected by patents and proprietary formulations which cannot be duplicated. With over 20 years of pharmaceutical drug delivery experience, Ovation's management and science team have created a unique pipeline of proprietary medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from royalties on licensees' sales and the sale of Invisicare, along with revenue from its own product sales. Ovation has offices in Vancouver, Canada and Las Vegas, USA.
Stock symbols: CSE:OVAT and OTC:OVATF
Websites: CORPORATE: www.ovationscience.com
WELLNESS: www.invibemd.com BEAUTY: www.arlocbdbeauty.com
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance of sales and acceptance of its products in any of the state or country cited, continued sales in dispensaries or in retail markets or expansion to other states or countries. There are no guarantees of future performance or changes to regulations. Ovation Science Inc. cautions that all forward-looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.'s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.
Neither the Canadian Securities Exchange, OTC Markets nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
CORPORATE and LICENSING INQUIRIES:
Doreen McMorran: [email protected] PH: 604-982-5700
SOURCE: Ovation Science Inc.
View the original press release on ACCESS Newswire
N.Mitchell--AT